我们的见解
The 2026 Pharmaceutical Paradigm Shift: China’s Global Ambitions Post-Drug Regulation Reform and the Challenges for Taiwan
On December 31, 2025, the State Council Executive Meeting officially reviewed and approved the "Regulations for the Implementation of the Drug Administration Law of the People's Republic of China (Revised Draft)"...
The 2026 Pharmaceutical Paradigm Shift: China’s Global Ambitions Post-Drug Regulation Reform and the Challenges for Taiwan
On December 31, 2025, the State Council Executive Meeting officially reviewed and approved the "Regulations for the Implementation of the Drug Administration Law of the People's Republic of China (Revised Draft)"...
Taiwan Biotech Industry Trend Analysis
Precision Medicine, Digital Innovation, and Global Market Integration In recent years, Taiwan’s biotech industry has gradually shaped a development framework centered on precision medicine, regenerative medicine, AI-enabled drug development, and...
Taiwan Biotech Industry Trend Analysis
Precision Medicine, Digital Innovation, and Global Market Integration In recent years, Taiwan’s biotech industry has gradually shaped a development framework centered on precision medicine, regenerative medicine, AI-enabled drug development, and...
Japan Pharmaceutical Market Entry Strategy
Japan Pharmaceutical Market Entry Strategy #Strategic Overview Japan is not a “get approval, then sell” market. It is a five-ring system that requires synchronized alignment across regulatory license holding,...
Japan Pharmaceutical Market Entry Strategy
Japan Pharmaceutical Market Entry Strategy #Strategic Overview Japan is not a “get approval, then sell” market. It is a five-ring system that requires synchronized alignment across regulatory license holding,...
Ten Years of Taiwan’s New Southbound Policy in Biotech: From “Relocation” to “Deep Rooting”
As the New Southbound Policy enters its tenth year, geopolitics and supply-chain reconfiguration have pushed Taiwanese firms to diversify risk. In manufacturing and ICT, results are visible. In biotechnology, however,...
Ten Years of Taiwan’s New Southbound Policy in Biotech: From “Relocation” to “Deep Rooting”
As the New Southbound Policy enters its tenth year, geopolitics and supply-chain reconfiguration have pushed Taiwanese firms to diversify risk. In manufacturing and ICT, results are visible. In biotechnology, however,...
The Global Pharmaceutical Industry and the Role of Generic Drugs
The Global Pharmaceutical Industry and the Role of Generic Drugs In the global pharmaceutical industry, multinational companies have long served as the driving force behind innovation. These corporations possess vast...
The Global Pharmaceutical Industry and the Role of Generic Drugs
The Global Pharmaceutical Industry and the Role of Generic Drugs In the global pharmaceutical industry, multinational companies have long served as the driving force behind innovation. These corporations possess vast...
Challenges and Prospects for Taiwan's New Drug Development
Challenges and Prospects for Taiwan's New Drug Development The Taiwanese government, through platforms like the Biotechnology and Pharmaceutical Industry Strategic Advisory Board (BTC), is actively integrating the nation’s...
Challenges and Prospects for Taiwan's New Drug Development
Challenges and Prospects for Taiwan's New Drug Development The Taiwanese government, through platforms like the Biotechnology and Pharmaceutical Industry Strategic Advisory Board (BTC), is actively integrating the nation’s...
